[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children
Launched by CHILDREN'S HOSPITAL MEDICAL CENTER, CINCINNATI · Nov 8, 2007
Trial Information
Current as of July 22, 2025
Withdrawn
Keywords
ClinConnect Summary
The first phase of the study will investigate if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue. Tne subjects between ages 5 and 17 years will be studies, to determine if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue. Drug safety will also be monitored.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented brain tumor at diagnosis or relapse, including high grade glioma, low grade glioma, medulloblastoma including PNET, optic pathway glioma, brainstem glioma, ependymoma.
- Exclusion Criteria:
- • Pregnancy
- • Requirement for sedation
- • Lack of informed consent
About Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center in Cincinnati is a leading pediatric healthcare institution dedicated to advancing child health through innovative clinical research and comprehensive patient care. Renowned for its commitment to excellence, the center conducts a wide range of clinical trials aimed at developing and evaluating new treatments and therapies for pediatric populations. With a focus on multidisciplinary collaboration and ethical research practices, Children's Hospital Medical Center strives to improve health outcomes for children while contributing to the broader scientific understanding of pediatric medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Michael J Gelfand, M.D.
Principal Investigator
Cincinnati Children's Hospital, Cincinnati, OH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials